Summary of Weight and Weight Change from Baseline at End of Treatment
Study CDISCPILOT01 — Safety Analysis Set
	Placebo	Xanomeline Low Dose	Xanomeline High Dose	
	(N=86)	(N=84)	(N=84)	
Weight (kg)				
Baseline				
n	86	83	84	
Mean (SD)	62.8 (12.77)	67.3 (14.13)	70.0 (14.65)	
Median	60.6	64.9	69.2	
Min, Max	34.0, 86.2	45.4, 106.1	41.7, 108.0	
Week 24				
n	59	27	30	
Mean (SD)	63.2 (12.58)	67.4 (14.07)	71.1 (15.82)	
Median	63.5	62.6	68.7	
Min, Max	34.0, 86.6	45.5, 106.1	49.9, 105.7	
End of treatment				
n	84	84	81	
Mean (SD)	63.3 (12.66)	66.7 (14.32)	69.7 (14.00)	
Median	64.0	65.9	70.3	
Min, Max	34.0, 86.6	41.7, 106.1	42.2, 105.7	
Weight change from baseline (kg)				
Week 24				
n	59	27	30	
Mean (SD)	0.1 (2.30)	-0.3 (2.04)	1.0 (6.47)	

Summary of Weight and Weight Change from Baseline at End of Treatment
Study CDISCPILOT01 — Safety Analysis Set
	Placebo	Xanomeline Low Dose	Xanomeline High Dose	
	(N=86)	(N=84)	(N=84)	
Median	0.0	0.0	-0.2	
Min, Max	-4.5, 8.2	-5.4, 3.2	-4.5, 33.3	
End of treatment				
n	84	83	81	
Mean (SD)	0.2 (2.05)	-0.4 (2.41)	0.1 (4.19)	
Median	0.0	0.0	-0.4	
Min, Max	-4.5, 8.2	-14.5, 5.9	-5.5, 33.3	
Treatment groups are PLANNED treatment (TRT01P). Twelve subjects in this study received a treatment other than the one they were randomised to; grouping by actual treatment (TRT01A) would give column sizes of 86, 96 and 72.
Baseline is the subject's observed Week 0 weight. Change from baseline is that subject's value minus that baseline, so a subject with no Week 0 weight contributes to the weight rows but not to the change rows.
End of treatment is the last observed weight at a planned visit after Week 0 up to and including Week 24. Unscheduled visits, the Week 26 follow-up visit and records derived by averaging or carry-forward are never selected.
n is the number of subjects contributing a measurement; N in the column header is the number of subjects in the safety analysis set.	
Source: advs, adsl (pharmaverseadam). Data cut-off: 2014-07-01. open.csr display t-weight (post-text variant); generated from the committed ARD.